| 1 |
Hershko-moshe A, Hasin Y, Nevo-shor A, Etzion O, Ilan Y. Improving the Treatment Response of Patients with Irritable Bowel Syndrome: Implementing a Second-Generation Artificial Intelligence System for Overcoming Resistance. GastroHep 2022;2022:1-12. [DOI: 10.1155/2022/1192547] [Reference Citation Analysis]
|
| 2 |
Muratore A, Shah ED, Chan WW. Cost-Benefit Analysis of Hydrogen Breath Test-Directed Rifaximin for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00907-7. [PMID: 36152896 DOI: 10.1016/j.cgh.2022.09.010] [Reference Citation Analysis]
|
| 3 |
Shah ED, Wechsler EV. Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Aliment Pharmacol Ther 2022;56:892-3. [PMID: 35934848 DOI: 10.1111/apt.17143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Shah ED. Delta Variant: Expanding the Indication for Eluxadoline to Bile Acid Diarrhea. Dig Dis Sci 2022;67:3481-2. [PMID: 35122590 DOI: 10.1007/s10620-022-07386-y] [Reference Citation Analysis]
|
| 5 |
Shute A, Bihan DG, Lewis IA, Nasser Y. Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission. Front Neurosci 2022;16:917197. [DOI: 10.3389/fnins.2022.917197] [Reference Citation Analysis]
|
| 6 |
Shah ED, Amann ST, Hobley J, Islam S, Taunk R, Wilson L. 2021 National Survey on Prior Authorization Burden and Its Impact on Gastroenterology Practice. Am J Gastroenterol 2022;117:802-5. [PMID: 35296630 DOI: 10.14309/ajg.0000000000001728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Shah ED, Brenner DM, Chen VL. Baseline Predictors of Discontinuation of Prescription Drug Therapy for IBS-C: Cohort Analysis at an Integrated Healthcare System. Dig Dis Sci 2022;67:1213-21. [PMID: 33779879 DOI: 10.1007/s10620-021-06963-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis. Clin Gastroenterol Hepatol 2022;20:136-144.e31. [PMID: 33010413 DOI: 10.1016/j.cgh.2020.09.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 9 |
Shah ED, Chang L, Lembo A, Staller K, Curley MA, Chey WD. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. Dig Dis Sci 2021;66:4140-8. [PMID: 33433804 DOI: 10.1007/s10620-020-06806-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 10 |
Wechsler EV, Shah ED. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options. Drugs 2021;81:1953-68. [PMID: 34727333 DOI: 10.1007/s40265-021-01634-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 11 |
Shah ED, Staller K, Nee J, Ahuja NK, Chan WW, Lembo A, Brenner DM, Siegel CA, Chey WD. Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis. Am J Gastroenterol 2021;116:2118-27. [PMID: 34388141 DOI: 10.14309/ajg.0000000000001403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 12 |
Eric D. Shah, Jessica K. Salwen-Deremer, Peter R. Gibson, Jane G. Muir, Shanti Eswaran, William D. Chey. Pharmacologic, Dietary, and Psychological Treatments for Irritable
Bowel Syndrome With Constipation: Cost Utility Analysis. MDM Policy Pract 2021;6:2381468320978417. [PMID: 33521290 DOI: 10.1177/2381468320978417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
